Publication
Rucaparib or Physician's Choice in Metastatic Prostate Cancer.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 26, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260926-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (8)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 8
- cancerCastration-Resistant Prostate Carcinomacivic_curation1.00
- drugRucaparibcivic_curation1.00
- geneATMcivic_curation1.00
- geneBRCA1civic_curation1.00
- geneBRCA2civic_curation1.00
- variantATM Mutationcivic_curation1.00
- variantBRCA1 Mutationcivic_curation1.00
- variantBRCA2 Mutationcivic_curation1.00
Curated evidence
Evidence citing this paper (4)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-17
- Retrieved
- Sep 17, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 36795891
- Run
- ING-CIVIC-20260917-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ATM Mutation1 | ||||||||
| Rucaparib | Castration-Resistant Prostate Carcinoma | Predictive | B | Does Not Support Sensitivity Response | 4 | accepted | EID13268In the exploratory ATM subgroup of the randomized phase III TRITON3 trial, 103 patients with metastatic castration-resistant prostate cancer harboring germline or somatic deleterious ATM alterations w… (full text at CIViC) PMID 36795891 · Fizazi et al., 2023 · Open in CIViC | civic |
| BRCA1 Mutation1 | ||||||||
| Rucaparib | Castration-Resistant Prostate Carcinoma | Predictive | B | Does Not Support Sensitivity Response | 3 | submitted | EID13266In a prespecified subgroup analysis of the randomized phase III TRITON3 trial, patients with metastatic castration-resistant prostate cancer harboring germline or somatic deleterious BRCA1 alterations… (full text at CIViC) PMID 36795891 · Fizazi et al., 2023 · Open in CIViC | civic |
| BRCA1 Mutation + BRCA2 MutationBRCA2BRCA11 | ||||||||
| Rucaparib | Castration-Resistant Prostate Carcinoma | Predictive | A | Supports Sensitivity Response | 5 | accepted | EID12944In the BRCA-altered cohort (n = 302; deleterious BRCA1/2 alterations) of the global, randomized, open-label phase III TRITON3 trial (NCT02975934) in mCRPC, pts treated with rucaparib (600 mg twice/day… (full text at CIViC) PMID 36795891 · Fizazi et al., 2023 · Open in CIViC | civic |
| BRCA2 Mutation1 | ||||||||
| Rucaparib | Castration-Resistant Prostate Carcinoma | Predictive | B | Supports Sensitivity Response | 4 | submitted | EID13267In a prespecified subgroup analysis of the randomized phase III TRITON3 trial, patients with metastatic castration-resistant prostate cancer harboring germline or somatic deleterious BRCA2 alterations… (full text at CIViC) PMID 36795891 · Fizazi et al., 2023 · Open in CIViC | civic |